Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olverembatinib in SDH-Deficient GIST (POLARIS-3)
NCT06640361Phase 3Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Nov 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of olverembatinib in gastrointestinal stromal tumor (GIST), sponsored by Ascentage Pharma. Primary endpoint: Progression-Free Survival Rate at 36 months. Started Nov 2024; status: recruiting.
02
Drugs
olverembatinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT06640361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06640361.